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Development of case scenarios to support decisions on polypharmacy reviews 
 
Elkin G, Kinnear A, Kinnear M.  
NHS Lothian Pharmacy Service, Edinburgh 
 
Background 
National guidance provides support for undertaking polypharmacy reviews1. Knowledge and 
experience is required to interpret the guidance in individual patients. Training materials 
using case examples developed by experts may help the application of guidance for less 
experienced practitioners. 
 
Objective 
Obtain consensus among consultant physicians and senior pharmacists on decisions to 
continue, modify or stop medicines in three different polypharmacy case scenarios. 
 
Methods 
Case scenarios were designed using examples from Medicine of the Elderly hospital 
practice which included at least three co-morbidities in patients from a range of social care 
settings. Cases one, two and three included 22, 19 and 25 medicines respectively. A 
questionnaire was developed to allow an expert panel to record whether they would 
continue, modify or stop each medicine for each scenario. The questionnaire was piloted 
with one consultant physician and specialist pharmacist. An e-mail invitation letter and copy 
of the STOPP/START criteria2 were sent in April 2014 to 37 consultant physicians and 19 
senior pharmacists in one regional NHS board with a link to the online questionnaire. A 
reminder email was sent to physicians from the clinical director and to pharmacists from the 
specialist pharmacist one week prior to the questionnaire closing. Responses from the final 
panel of 8 (22%) physicians and 14 (74%) pharmacists were collated using SurveyMonkey®. 
Consensus was defined as 75% of the experts reaching the same decisions. This study did 
not require ethics approval. 
 
Results 
Consensus (i.e. 75% of the panel) was reached for 13/22 (59%) medicines in case one, 
17/19 (89%) medicines in case two and 19/25 (76%) in case three (overall consensus 74%, 
49/66 medicines). Situations where consensus was not reached included anticholinergics in 
dementia patients, vasodilators in patient with recurrent falls, and laxatives. Panel comments 
included importance of considering additional patient details (e.g. pain scores, bowel charts) 
and family/patient wishes that would aid decision making.  
 
No apparent difference was observed between the two professional groups but physician 
variability was evident. For example in case one, one consultant stopped 6/22 medicines 
whilst another stopped 16/22 medicines, case two 4/19 medicines were stopped versus 
12/19, and for case three 4/25 medicines stopped versus 10/25. Similar physician variability 
was observed for continuing/modifying medicines. 
 
Conclusions 
Consensus was reached to continue, modify or stop for 74% of medicines within three 
polypharmacy case scenarios. A range of practice opinions were captured which are unlikely 
to be broader with a larger panel. It is proposed to use the case scenarios in facilitated 
discussion/teaching sessions, supported by a IDFLOLWDWRU¶V brief incorporating the additional 
comments from the panel, for training junior members of the multidisciplinary team to carry 
out polypharmacy reviews. Evaluation will include review and development of scenarios. 
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